Effects of Protein and Calorie Restriction on the Metabolism and Toxicity Profile of Irinotecan in Cancer Patients.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
19
05
2020
accepted:
06
10
2020
pubmed:
30
10
2020
medline:
16
9
2021
entrez:
29
10
2020
Statut:
ppublish
Résumé
Preclinical data suggests that protein and calorie restriction (PCR) might improve treatment tolerability without impairing antitumor efficacy. Therefore, we have studied the influence of PCR on irinotecan pharmacokinetics and toxicity. In this crossover trial, patients with liver metastases of solid tumors were included and randomized to treatment with irinotecan preceded by 5 days of PCR (~ 30% caloric and ~ 70% protein restriction) during the first cycle and a second cycle preceded by a normal diet or vice versa. Pharmacokinetic blood sampling and biopsies of both healthy liver and liver metastases were performed. The primary end point was the relative difference in geometric means for the active metabolite SN-38 concentration in healthy liver analyzed by a linear mixed model. No significant differences were seen in irinotecan (+ 16.8%, P = 0.22) and SN-38 (+ 9.8%, P = 0.48) concentrations between PCR and normal diet in healthy liver, as well as in liver metastases (irinotecan: -38.8%, P = 0.05 and SN-38: -13.8%, P = 0.50). PCR increased irinotecan plasma area under the curve from zero to 24 hours (AUC
Substances chimiques
Irinotecan
7673326042
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1304-1313Informations de copyright
© 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.
Références
de Man, F.M., Goey, A.K.L., van Schaik, R.H.N., Mathijssen, R.H.J. & Bins, S. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin. Pharmacokinet. 57, 1229-1254 (2018).
Mathijssen, R.H. et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7, 2182-2194 (2001).
Huisman, S.A., Bijman-Lagcher, W., IJzermans, J.N.M., Smits, R. & de Bruin, R.W.F. Fasting protects against the side effects of irinotecan but preserves its anti-tumor effect in Apc15lox mutant mice. Cell Cycle 14, 2333-2339 (2015).
Huisman, S.A. et al. Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice. Br. J. Pharmacol. 173, 804-814 (2016).
Lee, C. et al. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 70, 1564-1572 (2010).
Raffaghello, L. et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc. Natl. Acad. Sci. USA 105, 8215-8220 (2008).
Lee, C. et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci. Transl. Med. 4, 124ra27 (2012).
Safdie, F.M. et al. Fasting and cancer treatment in humans: a case series report. Aging (Albany, NY) 1, 988-1007 (2009).
Lee, C., Raffaghello, L. & Longo, V.D. Starvation, detoxification, and multidrug resistance in cancer therapy. Drug Resist. Updates 15, 114-122 (2012).
Fontana, L., Weiss, E.P., Villareal, D.T., Klein, S. & Holloszy, J.O. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. Aging Cell 7, 681-687 (2008).
Hine, C. et al. Endogenous hydrogen sulfide production is essential for dietary restriction benefits. Cell 160, 132-144 (2015).
Verweij, M. et al. Preoperative fasting protects mice against hepatic ischemia/reperfusion injury: mechanisms and effects on liver regeneration. Liver Transpl. 17, 695-704 (2011).
Jongbloed, F. et al. Preoperative fasting protects against renal ischemia-reperfusion injury in aged and overweight mice. PLoS One 9, e100853 (2014).
Jongbloed, F. et al. A signature of renal stress resistance induced by short-term dietary restriction, fasting, and protein restriction. Sci. Rep. 7, 40901 (2017).
Mitchell, J.R. et al. Short-term dietary restriction and fasting precondition against ischemia reperfusion injury in mice. Aging Cell 9, 40-53 (2010).
Conklin, K.A. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr. Cancer Ther. 3, 294-300 (2004).
Rtibi, K., Selmi, S., Grami, D., Sebai, H., Amri, M. & Marzouki, L. Irinotecan chemotherapy-induced intestinal oxidative stress: underlying causes of disturbed mucosal water and electrolyte transport. Pathophysiology 24, 275-279 (2017).
de Jong, F.A., Mathijssen, R.H., Xie, R., Verweij, J. & Sparreboom, A. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin. Cancer Res. 10, 4068-4071 (2004).
COSMED: The Metabolic Company <https://www.cosmed.com/en/products/body-composition>.
Hills, A.P., Mokhtar, N. & Byrne, N.M. Assessment of physical activity and energy expenditure: an overview of objective measures. Front. Nutr. 1, 5 (2014).
Jongbloed, F. et al. Short-term preoperative calorie and protein restriction is feasible in healthy kidney donors and morbidly obese patients scheduled for surgery. Nutrients 8, 306 (2016).
de Bruijn, P., Verweij, J., Loos, W.J., Nooter, K., Stoter, G. & Sparreboom, A. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B Biomed. Sci. Appl. 698, 277-285 (1997).
Chabot, G.G. et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann. Oncol. 6, 141-151 (1995).
Schoenfeld, D.A.Statistical considerations for a cross-over study where the outcome is a measurement <http://hedwig.mgh.harvard.edu/sample_size/js/js_crossover_quant.html>. Accessed September, 21, 2015.
European Medicines Agency http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/>.
Jones, B. Design and analysis of cross-over trials, 2nd edn (Chapman & Hall/CRC, Tucson, AZ, 2003).
Lammers, L.A., Achterbergh, R., Romijn, J.A. & Mathot, R.A.A. Nutritional status differentially alters cytochrome P450 3A4 (CYP3A4) and uridine 5'-diphospho-glucuronosyltransferase (UGT) mediated drug metabolism: effect of short-term fasting and high fat diet on midazolam metabolism. Eur. J. Drug Metab. Pharmacokinet. 43, 751-767 (2018).
Kamal, S. et al. The frequency, clinical course, and health related quality of life in adults with Gilbert's syndrome: a longitudinal study. BMC Gastroenterol. 19, 22 (2019).
Kulkarni, S.R. et al. Fasting induces nuclear factor E2-related factor 2 and ATP-binding Cassette transporters via protein kinase A and Sirtuin-1 in mouse and human. Antioxid. Redox Signal 20, 15-30 (2014).
Xu, J. et al. Hepatic carboxylesterase 1 is induced by glucose and regulates postprandial glucose levels. PLoS One 9, e109663 (2014).
Xu, Z. & Knight, R. Dietary effects on human gut microbiome diversity. Br. J. Nutr. 113 (suppl.), S1-S5 (2015).
Lammers, L.A., Achterbergh, R., van Schaik, R.H.N., Romijn, J.A. & Mathot, R.A.A. Effect of short-term fasting on systemic cytochrome P450-mediated drug metabolism in healthy subjects: a randomized, controlled, crossover study using a cocktail approach. Clin. Pharmacokinet. 56, 1231-1244 (2017).
Hatfield, M.J. et al. Carboxylesterases: general detoxifying enzymes. Chem. Biol. Interact. 259, 327-331 (2016).
Martignoni, M., Groothuis, G.M. & de Kanter, R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol. 2, 875-894 (2006).
de Groot, S. et al. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer 15, 652 (2015).
Dorff, T.B. et al. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer 16, 360 (2016).
Bauersfeld, S.P. et al. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer 18, 476 (2018).